(Q34569970)

3 August 2017

1 reference

title

The biological treatment of renal-cell carcinoma and melanoma (English)

1 reference

3 August 2017

Paul D Nathan

1

1 reference

PubMed ID

11902528

3 August 2017

Tim G Eisen

series ordinal

2

1 reference

3 August 2017

1 February 2002

1 reference

Lancet Oncology Commission

3 August 2017

1 reference

3 August 2017

3

1 reference

3 August 2017

89-96

1 reference

3 August 2017

2

1 reference

Improved prognostication of renal cell carcinoma using an integrated staging system

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

A new American Joint Committee on Cancer staging system for cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

Gender and other survival predictors in patients with metastatic melanoma on Southwest Oncology Group trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

Proceedings: Hormone-induced and spontaneous regression of metastatic renal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

Spontaneous regression of metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

Regimens with or without interferon-alpha as treatment for metastatic melanoma and renal cell carcinoma: an overview of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

Paroxetine for the prevention of depression induced by high-dose interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

Interleukin-2 toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

New approaches to the systemic treatment of melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

Tumor antigens recognized by T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

MAGE-B5, MAGE-B6, MAGE-C2, andMAGE-C3: four new members of theMAGE family with tumor-specific expression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guèrin: five-year results of a prospective randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

The use of dendritic cells in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

Thalidomide is an inhibitor of angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

Interleukin-6 and renal cell cancer: production, regulation, and growth effects

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

Evidence that tumor necrosis factor plays a pathogenetic role in the paraneoplastic syndromes of cachexia, hypercalcemia, and leukocytosis in a human tumor in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

Activity of thalidomide in AIDS-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

Farnesyl transferase inhibitors: a novel targeted tnerapy for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900650-2

7 January 2021

10.1016/S1470-2045(02)00650-2

Identifiers

DOI

1 reference

3 August 2017

1 reference

PubMed ID

11902528